These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24533804)

  • 1. Peptide prodrugs for the treatment of CNS disorders: a perspective for new drugs.
    Chin CM; Chiba DE; Machado MG; Vizioli Ede O; Santos JL
    Curr Med Chem; 2014; 21(23):2599-609. PubMed ID: 24533804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prodrug strategy for enhanced therapy of central nervous system disease.
    Xia X; Zhou Y; Gao H
    Chem Commun (Camb); 2021 Sep; 57(71):8842-8855. PubMed ID: 34486590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide therapeutics for CNS indications.
    McGonigle P
    Biochem Pharmacol; 2012 Mar; 83(5):559-66. PubMed ID: 22051078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrug approaches to reduce hyperexcitation in the CNS.
    Vytla D; Combs-Bachmann RE; Hussey AM; McCarron ST; McCarthy DS; Chambers JJ
    Adv Drug Deliv Rev; 2012 May; 64(7):666-85. PubMed ID: 22138074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The blood-brain barrier: clinical implications for drug delivery to the brain.
    De Boer AG; Breimer DD
    J R Coll Physicians Lond; 1994; 28(6):502-6. PubMed ID: 7884704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The CNS as a target for peptides and peptide-based drugs.
    Banks WA
    Expert Opin Drug Deliv; 2006 Nov; 3(6):707-12. PubMed ID: 17076593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptides: important tools for the treatment of central nervous system disorders.
    Malavolta L; Cabral FR
    Neuropeptides; 2011 Oct; 45(5):309-16. PubMed ID: 21477861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.
    Peura L; Malmioja K; Laine K; Leppänen J; Gynther M; Isotalo A; Rautio J
    Mol Pharm; 2011 Oct; 8(5):1857-66. PubMed ID: 21770378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding and circumventing the blood-brain barrier.
    Begley DJ
    Acta Paediatr Suppl; 2003 Dec; 92(443):83-91. PubMed ID: 14989470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
    Kanazawa T
    Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Small endogenous molecules as moiety to improve targeting of CNS drugs.
    Sutera FM; De Caro V; Giannola LI
    Expert Opin Drug Deliv; 2017 Jan; 14(1):93-107. PubMed ID: 27367188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prodrugs and endogenous transporters: are they suitable tools for drug targeting into the central nervous system?
    Pavan B; Dalpiaz A
    Curr Pharm Des; 2011; 17(32):3560-76. PubMed ID: 22074427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell-Penetrating Peptides: As a Promising Theranostics Strategy to Circumvent the Blood-Brain Barrier for CNS Diseases.
    Varnamkhasti BS; Jafari S; Taghavi F; Alaei L; Izadi Z; Lotfabadi A; Dehghanian M; Jaymand M; Derakhshankhah H; Saboury AA
    Curr Drug Deliv; 2020; 17(5):375-386. PubMed ID: 32294035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents.
    Prokai-Tatrai K; Prokai L
    Molecules; 2009 Feb; 14(2):633-54. PubMed ID: 19214153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Start small and stay small. Minimizing attrition in the clinic with a focus on CNS therapeutics.
    Nienaber V
    Curr Top Med Chem; 2009; 9(18):1688-704. PubMed ID: 19929834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery.
    Vlieghe P; Khrestchatisky M
    Med Res Rev; 2013 May; 33(3):457-516. PubMed ID: 22434495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug delivery to the CNS and polymeric nanoparticulate carriers.
    Costantino L
    Future Med Chem; 2010 Nov; 2(11):1681-701. PubMed ID: 21428839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prodrugs in nasal drug delivery.
    Tirucherai GS; Yang C; Mitra AK
    Expert Opin Biol Ther; 2001 Jan; 1(1):49-66. PubMed ID: 11727547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Azomethine prodrugs of (R)-alpha-methylhistamine, a highly potent and selective histamine H3-receptor agonist.
    Krause M; Stark H; Schunack W
    Curr Med Chem; 2001 Sep; 8(11):1329-40. PubMed ID: 11562269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peptide pills for brain diseases? Reality and future perspectives.
    Serrano Lopez DR; Lalatsa A
    Ther Deliv; 2013 Apr; 4(4):479-501. PubMed ID: 23557289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.